WASHINGTON, May 25 2022 – The Securing America’s Medicines and Supply (SAMS) coalition today commented on the Biomedical Advanced Research & Development Authority’s (BARDA) five-year Strategic Plan to strengthen the nation’s pandemic preparedness capabilities, expand public-private partnerships, and invest in the organization’s workforce.
“SAMS applauds BARDA for its mission to fortify the nation’s health security. BARDA’s role in fostering public-private partnerships with U.S. corporations have been the cornerstone of the America’s response to the COVID-19 pandemic. These partnerships have resulted in the development of life-saving therapies, reduced the country’s dependence on overseas manufacturing, and invigorated domestic supply chains within the United States. As BARDA continues to bolster these partnerships, SAMS is encouraged by calls to expand domestic production of complex biologics, biosimilars, generics, and other drugs and medical supplies. As it reviews the Administration’s proposed budget, we encourage Congress to work in a bipartisan fashion to ensure BARDA has the resources to continue this important work and successfully execute its Strategic Plan. In doing so, the federal government can ensure Americans are protected against the ongoing COVID-19 pandemic, future emerging infectious diseases, and other looming public health threats.”David T. Sanders, SAMS Executive Director
About Securing America’s Medicines and Supply
Securing America’s Medicines and Supply (SAMS) is a multi-industry coalition of companies with the mission to strengthen the security of the medical supply chain in the United States. SAMS seeks to drive implementation of legislation and regulation to reward and foster U.S.-made manufacturing of important pharmaceutical products, devices, and supplies. SAMS supports U.S. patients, domestic healthcare security, and U.S. jobs.